BioNTech SE - ADR

NASDAQ:BNTX   10:16:35 AM EDT
167.13
-15.98 (-8.73%)
Products, Strategic Combinations

BioNTech And Genmab Expand Global Strategic Collaboration To Develop Novel Immunotherapy Candidates

Published: 08/05/2022 12:01 GMT
BioNTech SE - ADR (BNTX) - Biontech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates.
Biontech Se - First Monospecific Antibody Candidate Gen1053/bnt313 Planned to Enter Clinical Trials by End of 2022.
Biontech Se - Biontech and Genmab Will Share Costs and Potential Future Profits on a 50:50 Basis.
Biontech Se - Expanded Collaboration Leverages Genmab's Proprietary Hexabody(®) Technology Platform to Develop Novel Immunotherapies.